<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Calidi Biotherapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc</link>
<description>Latest news and press releases for Calidi Biotherapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/calidi-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7429f51cc36e47533196c.webp</url>
<title>Calidi Biotherapeutics, Inc.</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc</link>
</image>
<item>
<title>Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 21 2026. The Company showcased new data on CLD-401, a systemically delivered oncolytic virus that is designed to express h</description>
</item>
<item>
<title>Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-participation-in-redchips-april-16-virtual-investor-conference-to-feature-companies-advancing-clinical-pipelines-and-scalable-healthcare-platforms</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-participation-in-redchips-april-16-virtual-investor-conference-to-feature-companies-advancing-clinical-pipelines-and-scalable-healthcare-platforms</guid>
<pubDate>Wed, 15 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in RedChip’s upcoming virtual investor conference, “Biotech Resurgence: Platforms and Pipelines of Today’s Innovators,” taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. E.T. The full-day event will spotlight publicly traded companies advancing innovation across biote</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjavik-iceland-on-april-28th-highlighting-the-redtail-platforms-ability-to-deliver-genetic-medicines-to-distal-sites-of-disease-with-systemic-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjavik-iceland-on-april-28th-highlighting-the-redtail-platforms-ability-to-deliver-genetic-medicines-to-distal-sites-of-disease-with-systemic-therapy</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present at the Internation Oncolytic Virus Conference (IOVC) in Reykjavik, Iceland on April 28th, 2026. The Company will present data on its RedTail platform and its lead compound CLD-401. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tum</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-14-2026-highlighting-the-redtail-platforms-ability-to-deliver-genetic-medicines-to-distal-sites-of-disease-with-systemic-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-14-2026-highlighting-the-redtail-platforms-ability-to-deliver-genetic-medicines-to-distal-sites-of-disease-with-systemic-therapy</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors</description>
</item>
<item>
<title>Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026-62</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026-62</guid>
<pubDate>Thu, 02 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will showcase new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist (“</description>
</item>
<item>
<title>Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the-aacr-annual-meeting-in-april-2026</guid>
<pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically</description>
</item>
<item>
<title>Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-operational-highlights</guid>
<pubDate>Fri, 27 Mar 2026 20:25:00 GMT</pubDate>
<description>Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026Partnered with Matica Bio around the GMP manufacturing of CLD-401Presented new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conferenceRaised $6.5 million in publ</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-partnership-with-avance-clinical-to-facilitate-australian-regulatory-approval-and-accelerate-initiation-of-cld-401-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-partnership-with-avance-clinical-to-facilitate-australian-regulatory-approval-and-accelerate-initiation-of-cld-401-clinical-trials</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced a partnership with Avance Clinical, a full-service contract research organization (CRO) with a proven track record and experience in obtaining regulatory approval and clinical trial initiation in Australia. The partnership is focused on rapidly initiating a first-in-human cli</description>
</item>
<item>
<title>Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-its-innovative-and-scalable-manufacturing-process-for-cld-401-at-the-9th-annual-bioprocessing-summit-fda-feedback-support-companys-approach-to-manufacturing-3</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-its-innovative-and-scalable-manufacturing-process-for-cld-401-at-the-9th-annual-bioprocessing-summit-fda-feedback-support-companys-approach-to-manufacturing-3</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary manufacturing process for CLD-401, the Company’s first lead candidate from its RedTail platform, at the BioProcessing Summit in Barcelona. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumor cells, remodel th</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-closing-of-dollar60-million-underwritten-public-offering-and-full-exercise-of-underwriters-over-allotment-option</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-closing-of-dollar60-million-underwritten-public-offering-and-full-exercise-of-underwriters-over-allotment-option</guid>
<pubDate>Tue, 10 Mar 2026 00:50:00 GMT</pubDate>
<description>$12 Million of Tranche Warrants Potential Financing Within One Year From ClosingSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of approximately $6.0 million, prior to</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-pricing-of-dollar52-million-underwritten-public-offering-35</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-pricing-of-dollar52-million-underwritten-public-offering-35</guid>
<pubDate>Fri, 06 Mar 2026 13:30:00 GMT</pubDate>
<description>Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of ClosingSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the pricing of its underwritten public offering of 10,519,631 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof), (ii) one 6 month warrant</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-proposed-public-offering-10</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-proposed-public-offering-10</guid>
<pubDate>Thu, 05 Mar 2026 22:57:00 GMT</pubDate>
<description>SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public of</description>
</item>
<item>
<title>Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company’s website.</description>
</item>
<item>
<title>Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-in-a-late-breaking-abstract-at-the-2026-aacr-io-conference</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-to-present-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-in-a-late-breaking-abstract-at-the-2026-aacr-io-conference</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it will present data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California, from February 18-21, 2026. RedTail is Calidi’s s</description>
</item>
<item>
<title>Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-provides-corporate-update-and-key-value-drivers-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-provides-corporate-update-and-key-value-drivers-for-2026</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-exclusive-live-investor-webinar-and-qanda-session-on-november-19-2025</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-exclusive-live-investor-webinar-and-qanda-session-on-november-19-2025</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on November 19, 2025, at 1:15 p.m. PT. The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into</description>
</item>
<item>
<title>Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-reports-third-quarter-2025-financial-results-and-recent-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-reports-third-quarter-2025-financial-results-and-recent-operational-highlights</guid>
<pubDate>Thu, 13 Nov 2025 21:15:00 GMT</pubDate>
<description>Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively express genetic medicines at the tumor siteEstablished new Scientific Advisory Board to support development of CLD-401 and advance RedTail platform for the systemic delivery of targeted genetic medicine Continued expansion of RedTail platform capabilities with multiple additional pay</description>
</item>
<item>
<title>Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-therapeutic-lead-cld-401-at-the-2025-sitc-annual-meeting-and-holds-its-first-investor-day-at-sitc</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-presents-new-data-on-its-therapeutic-lead-cld-401-at-the-2025-sitc-annual-meeting-and-holds-its-first-investor-day-at-sitc</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer (SITC) Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic admi</description>
</item>
<item>
<title>Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting</title>
<link>https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-investor-event-to-be-held-on-friday-november-7th-at-the-2025-sitc-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/calidi-biotherapeutics-inc/news/calidi-biotherapeutics-announces-investor-event-to-be-held-on-friday-november-7th-at-the-2025-sitc-annual-meeting</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting centered around the Company’s groundbreaking RedTail platform and its lead candidate, CLD-401. The presentation will take place at the SI</description>
</item>
</channel>
</rss>